Skip to main content

Advertisement

SpringerLink
Log in

Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Aromatase inhibitors and inactivators are increasingly important to the therapy of advanced breast cancer in postmenopausal women. These compounds are also currently being evaluated in the adjuvant setting and may have potential in breast cancer prevention. In addition to the recent clinical results, experimental research with development of aromatase ‘knockout’ mice as well as certain clinical observations in individuals lacking this enzyme have deepened our understanding of estrogens outside of the field of reproduction. Such information should help us to further develop this type of therapy in breast cancer and, in particular, extend our understanding of the lack of complete cross-resistance between aromatase inhibitors and inactivators. Clinically, third-generation aromatase inhibitors and inactivators have shown superiority compared with conventional treatment in advanced postmenopausal breast cancer with respect to second-line (tamoxifen failures) as well as first-line therapy. The fact that tamoxifen is noncurative in metastatic disease but improves long-term survival in the adjuvant setting suggests that even modest improvements in therapy of advanced disease may be translated into survival benefits in patients with early disease. In addition, these novel compounds with lack of complete cross-resistance extend the scope of using sequential treatment options to maximise the duration of optimal endocrine therapy in metastatic breast cancer disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2
Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Fracchia AA, Farrow JH, DePalo AJ, et al. Castration for primary inoperable or recurrent breast carcinoma. Surg Gynecol Obstet 1969; 128: 1226–34

    PubMed  CAS  Google Scholar 

  2. Klijn JGM, Beex LVAM, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000; 92(11): 903–11

    Article  PubMed  CAS  Google Scholar 

  3. Allegra JC, Lippman ME, Thompson EB, et al. Relationship between the progesterone, androgen, and glucocorticoid receptor and response rate to endocrine therapy in metastatic breast cancer. Cancer Res 1979; 39: 1973–9

    PubMed  CAS  Google Scholar 

  4. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989; 49: 7162–7

    PubMed  CAS  Google Scholar 

  5. Lundgren S. Progestins in breast cancer treatment. Acta Oncol 1992; 31: 709–22

    Article  PubMed  CAS  Google Scholar 

  6. Lundgren S, Lønning PE. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer II: a differential effect of megestrol acetate on serum estrone sulfate and sex hormone binding globulin. J Steroid Biochem 1990; 36: 105–9

    Article  PubMed  CAS  Google Scholar 

  7. Lundgren S, Lønning PE, Utaaker E, et al. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-I. General findings. J Steroid Biochem 1990; 36(1–2): 99–104

    Article  PubMed  CAS  Google Scholar 

  8. Lundgren S, Helle SI, Lønning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996; 2: 1515–21

    PubMed  CAS  Google Scholar 

  9. Perrault D, Eisenhauer EA, Pritchard Kl, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996; 14: 2709–12

    PubMed  CAS  Google Scholar 

  10. Lamberts SWJ, Koper JW, deJong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991; 73(1): 187–91

    Article  PubMed  CAS  Google Scholar 

  11. Helle SI, Jonat W, Giurescu M, et al. Influence of treatment with onapristone on the IGF-system in breast cancer patients. J Steroid Biochem Mol Biol 1998; 66(3): 159–63

    Article  PubMed  CAS  Google Scholar 

  12. Nosaquo ND. Androgens and estrogens in the treatment of disseminated mammary carcinoma. JAMA 1960; 172: 135–47

    Google Scholar 

  13. Maggiolini M, Donze O, Jeannin E, et al. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 1999; 59(19): 4864–9

    PubMed  CAS  Google Scholar 

  14. Yeh SY, Miyamoto H, Shima H, et al. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A 1998; 95(10): 5527–32

    Article  PubMed  CAS  Google Scholar 

  15. Pasqualini JR. Role of androgens in breast cancer. J Steroid Biochem Mol Biol 1993; 45(1–3): 167–72

    Article  PubMed  CAS  Google Scholar 

  16. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998; 3(1): 95–103

    Article  PubMed  CAS  Google Scholar 

  17. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93: 5925–30

    Article  PubMed  CAS  Google Scholar 

  18. Mosselman S, Polman J, Dijkema R. ER ß identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53

    Article  PubMed  CAS  Google Scholar 

  19. Järvinen TAH, PeltoHuikko M, Holli K, et al. Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156(1): 29–35

    Article  PubMed  Google Scholar 

  20. Fuqua SAW, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999; 59(21): 5425–8

    PubMed  CAS  Google Scholar 

  21. Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at API sites. Science 1997; 277(5331): 1508–10

    Article  PubMed  CAS  Google Scholar 

  22. Onate SA, Tsai SY, Tsai M-J, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270: 1354–7

    Article  PubMed  CAS  Google Scholar 

  23. McKenna NJ, Xu JM, Nawaz Z, et al. Nuclear receptor co-activators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 1999; 69(1–6): 3–12

    Article  PubMed  CAS  Google Scholar 

  24. Geisler J, Lønning P. Resistance to endocrine therapy of breast cancer: recent advances and tomorrows challenges. Clin Breast Cancer 2001; 1: 297–308

    Article  PubMed  CAS  Google Scholar 

  25. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17(9): 2639–48

    PubMed  CAS  Google Scholar 

  26. Borg A, Baldetorp B, Ferno M, et al. erbB-2 amplification is associated with tamoxifen resistance in steroid receptor positive breast cancer. Cancer Lett 1994; 81: 137–44

    Article  PubMed  CAS  Google Scholar 

  27. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14(10): 2702–8

    PubMed  CAS  Google Scholar 

  28. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18(20): 3471–9

    PubMed  CAS  Google Scholar 

  29. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and /or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001; 19(18): 3808–16

    PubMed  CAS  Google Scholar 

  30. Lipton A, Mouridsen H, Ali S, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen [abstract]. Breast Cancer Res Treat 2001; 69: 210

    Google Scholar 

  31. Colletti RB, Roberts JD, Devlin JT, et al. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989; 49: 1882–4

    PubMed  CAS  Google Scholar 

  32. Lønning PE, Hall K, Aakvaag A, et al. Influence of tamoxifen on the plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992; 52: 4719–23

    PubMed  Google Scholar 

  33. Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990; 35: 355–66

    Article  PubMed  Google Scholar 

  34. Sluijmer AV, Heineman MJ, De Jong FH, et al. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995; 80: 2163–7

    Article  PubMed  CAS  Google Scholar 

  35. Couzinet B, Meduri G, Lecce MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86: 5060–6

    Article  PubMed  CAS  Google Scholar 

  36. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by isolated human hairs. J Clin Endocrinol Metab 1975; 40: 413–7

    Article  PubMed  CAS  Google Scholar 

  37. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by cultured human fibroblasts. J Clin Endocrinol Metab 1976; 43: 785–95

    Article  PubMed  CAS  Google Scholar 

  38. Frisch RE, Canick JA, Tulchinsky D. Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metab 1980; 51(2): 394–6

    Article  PubMed  CAS  Google Scholar 

  39. Perel E, Killinger DW. The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem 1978; 10: 623–7

    Article  Google Scholar 

  40. Smuk M, Schwers J. Aromatization of androstenedione by human adult liver in vitro. J Clin Endocrinol Metab 1977; 45(5): 1009–12

    Article  PubMed  CAS  Google Scholar 

  41. Matsumine H, Hirato K, Yanaihara T, et al. Aromatization by skeletal muscle. J Clin Endocrinol Metab 1984; 63(3): 717–20

    Article  Google Scholar 

  42. Longcope C, Johnston CC. Androgen and estrogen dynamics in pre- and postmenopausal women: a comparison between smokers and nonsmokers. J Clin Endocrinol Metab 1988; 67(2): 379–83

    Article  PubMed  CAS  Google Scholar 

  43. Lønning PE, Jacobs S, Jones A, et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 63: 789–93

    Article  PubMed  Google Scholar 

  44. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4: 2089–93

    PubMed  CAS  Google Scholar 

  45. Demers LM, Lipton A, Harvey HA, et al. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol 1993; 44: 687–91

    Article  PubMed  CAS  Google Scholar 

  46. Dowsett M, Goss PE, Powles TJ, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957–61

    PubMed  CAS  Google Scholar 

  47. Lønning PE, Helle SI, Johannessen DC, et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol (Oxf) 1995; 42(1): 23–30

    Article  Google Scholar 

  48. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74(8): 1286–91

    Article  PubMed  CAS  Google Scholar 

  49. Geisler J, Lien EA, Ekse D, et al. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1997; 63(1–3): 53–8

    Article  PubMed  CAS  Google Scholar 

  50. Geisler P, Lundgren S, Berntsen H, et al. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83(8): 2687–93

    Article  PubMed  CAS  Google Scholar 

  51. Lønning PE, Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol 1995; 55(3/4): 409–12

    Article  PubMed  Google Scholar 

  52. Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685–710

    Article  PubMed  Google Scholar 

  53. Lønning PE, Kvinnsland S, Thorsen T, et al. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet 1987; 13: 393–406

    Article  PubMed  Google Scholar 

  54. Lønning PE, Johannessen DC, Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989; 60: 107–11

    Article  PubMed  Google Scholar 

  55. Lønning PE, Johannessen DC, Thorsen T, et al. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. J Steroid Biochem 1989; 33: 541–5

    Article  PubMed  Google Scholar 

  56. Geisler J, Haynes B, Anker G, et al. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 2002; 20: 751–7

    Article  PubMed  CAS  Google Scholar 

  57. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–98

    Article  PubMed  CAS  Google Scholar 

  58. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–61

    Article  PubMed  CAS  Google Scholar 

  59. Jones MEE, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000; 97(23): 12735–40

    Article  PubMed  CAS  Google Scholar 

  60. Lonning PE, Kragh LE, Erikstein B, et al. The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res 2001; 7: 4423s–8s

    PubMed  CAS  Google Scholar 

  61. Edery M, Goussard J, Dehennin L, et al. Endogenous oestradiol-17ß concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer 1980; 17: 115–20

    Google Scholar 

  62. VanLandeghem AAJ, Poortman J, Nabuurs M, et al. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 1985; 45: 2900–4

    CAS  Google Scholar 

  63. Vermeulen A, Deslypere JP, Paridaens R, et al. Aromatase, 17ß-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1985; 22(4): 515–25

    Article  Google Scholar 

  64. Geisler J, Berntsen H, Ottestad L, et al. Neoadjuvant treatment with anastrozole (‘Arimidex’) causes profound suppression of intra-estrogen levels [abstract no. 311 ]. Proc Am Soc Clin Oncol 1999; 18: 82a

    Google Scholar 

  65. Fishman J, Nisselbaum JS, Menendez-Botet CJ, et al. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J Steroid Biochem 1977; 8: 893–6

    Article  PubMed  CAS  Google Scholar 

  66. Bulun SE, Price TM, Aitken J, et al. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome p450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993; 77: 1622–8

    Article  PubMed  CAS  Google Scholar 

  67. Lipton A, Santner SJ, Santen RJ, et al. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987; 59: 779–82

    Article  PubMed  CAS  Google Scholar 

  68. Miller WR, Anderson TJ, Jack WJL. Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 1990; 37(6): 1055–9

    Article  PubMed  CAS  Google Scholar 

  69. Reed MJ, Owen AM, Lai LC, et al. In situ oestrone synthesis in normal breast and breast tumour tissue; effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 1989; 44: 233–7

    Article  PubMed  CAS  Google Scholar 

  70. Perel E, Blackstein ME, Killinger DW. Aromatase in human breast carcinoma. Cancer Res 1982; 42Suppl. 8: 3369s–72s

    PubMed  CAS  Google Scholar 

  71. Silva MC, Rowlands MG, Dowsett M, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989; 49: 2588–91

    PubMed  CAS  Google Scholar 

  72. Sasano H, Murakami H. Immunolocalization of aromatase in human breast disorders using different antibodies. Breast Cancer Res Treat 1998; 49Suppl. 1: S79–84

    Article  PubMed  CAS  Google Scholar 

  73. Santen RJ, Martel J, Hoagland M, et al. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts. Breast Cancer Res Treat 1998; 49Suppl. 1: S93–9

    Article  PubMed  CAS  Google Scholar 

  74. Brodie A, Long B, Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 1998; 49Suppl. 1: S85–91

    Article  PubMed  CAS  Google Scholar 

  75. Shenton KC, Dowsett M, Lu Q, et al. Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas. Breast Cancer Res Treat 1998; 49Suppl. 1: S101–7

    Article  PubMed  CAS  Google Scholar 

  76. Masamura S, Santner SJ, Gimotty P, et al. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 1997; 42(3): 215–26

    Article  PubMed  CAS  Google Scholar 

  77. Chen S, Zhou D, Okubo T, et al. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999; 6: 149–56

    Article  PubMed  CAS  Google Scholar 

  78. Singh A, Purohit A, Ghilchik MW, et al. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 1999; 6: 139–47

    Article  PubMed  CAS  Google Scholar 

  79. Miller WR. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Dowsett M, editor. Aromatase inhibition -then, now and tomorrow. London: Parthenon Publishing Group, 1994: 43–53

    Google Scholar 

  80. Yue W, Bernstein L, Wang J, et al. Long term estrogen deprivation (LTED) enhances aromatase activity in breast cancer cells [abstract no. 2376]. Proc Am Assoc Cancer Res 2000; 41: 374

    Google Scholar 

  81. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000; 1Suppl. I: s9–14

    Article  PubMed  Google Scholar 

  82. Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 1995; 80: 3052–8

    Article  PubMed  CAS  Google Scholar 

  83. Reed MJ, Topping L, Coldham NG, et al. Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J Steroid Biochem Mol Biol 1993; 44: 589–96

    Article  PubMed  CAS  Google Scholar 

  84. Zhao Y, Nichols JE, Valdez R, et al. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 1996; 10(11): 1350–7

    Article  PubMed  CAS  Google Scholar 

  85. Oh SS, Robinson CH. Mechanism of human placental aromatase, a new active site model. J Steroid Biochem Mol Biol 1993; 44: 389–97

    Article  PubMed  CAS  Google Scholar 

  86. Laughton CA, Zvelebil MJJM, Neidle S. A detailed molecular modal for human aromatase. J Steroid Biochem Mol Biol 1993; 44: 399–407

    Article  PubMed  CAS  Google Scholar 

  87. Graham-Lorence S, Amarneh B, White RE, et al. A three-dimensional model of aromatase cytochrome p450. Protein Sci 1995; 4(6): 1065–80

    Article  PubMed  CAS  Google Scholar 

  88. Chen S, Kao YC, Laughton CA. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. J Steroid Biochem Mol Biol 1997; 61(3–6): 107–15

    Article  PubMed  CAS  Google Scholar 

  89. Zhao Y, Mendelson CR, Simpson ER. Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol 1995; 9: 340–9

    Article  PubMed  CAS  Google Scholar 

  90. Agarwal VR, Bulun SE, Leitch M, et al. Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996; 81(11): 3843–9

    Article  PubMed  CAS  Google Scholar 

  91. Simpson ER, Bulun SE, Nichols JE, et al. Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms. J Endocrinol 1996; 150 Suppl.: S51–7

    Article  PubMed  CAS  Google Scholar 

  92. Simpson E, Jones M, Davis S, et al. Do intracrine mechanisms regulate aromatase expression? J Steroid Biochem Mol Biol 1999; 69(1–6): 447–52

    Article  PubMed  CAS  Google Scholar 

  93. Yang C, Zhou DJ, Chen S. Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res 1998; 58(24): 5695–700

    PubMed  CAS  Google Scholar 

  94. Jacobs S, Lønning PE, Haynes B, et al. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib 1991; 4: 315–25

    Article  PubMed  CAS  Google Scholar 

  95. MacNeill FA, Jones AL, Jacobs S, et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992; 66: 692–7

    Article  PubMed  CAS  Google Scholar 

  96. MacNeill FA, Jacobs S, Dowsett M, et al. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995; 36: 249–54

    Article  PubMed  CAS  Google Scholar 

  97. Jones AL, MacNeill F, Jacobs S, et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28A(10): 1712–6

    Article  PubMed  CAS  Google Scholar 

  98. Dowsett M, Jones A, Johnston SRD, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511–5

    PubMed  CAS  Google Scholar 

  99. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16: 83–93

    Article  PubMed  CAS  Google Scholar 

  100. Lønning PE. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol 1990; 26: 241–4

    Article  PubMed  Google Scholar 

  101. Haynes BP, Jarman M, Dowsett M, et al. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 1991; 27: 367–72

    Article  PubMed  CAS  Google Scholar 

  102. Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer 1991; 64(5): 887–94

    Article  PubMed  CAS  Google Scholar 

  103. Santen RJ, Demers LM, Adlercreutz H, et al. Inhibition of aromatase with cgs 16949a in postmenopausal women. J Clin Endocrinol Metab 1989; 68(1): 99–106

    Article  PubMed  CAS  Google Scholar 

  104. Pfister C, Dowsett M, Iveson T, et al. Pharmacokinetics of new aromatase inhibitor CGS 20267. Eur J Drug Metab Phar-macokinet 1993; 18 Suppl.: 117

    Google Scholar 

  105. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103–11

    Article  PubMed  CAS  Google Scholar 

  106. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918–25

    Article  PubMed  CAS  Google Scholar 

  107. Furet P, Batzl C, Bhatnagar A, et al. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem 1993; 36(10): 1393–400

    Article  PubMed  CAS  Google Scholar 

  108. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of ‘Arimidex’ (anastrozole; ZD1033) -a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996; 58(4): 439–45

    Article  PubMed  CAS  Google Scholar 

  109. Dowsett M, Stein RC, Mehta A, et al. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990; 32: 623–34

    Article  CAS  Google Scholar 

  110. Bhatnagar AS, Hausier A, Schieweck K. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enzyme Inhib 1990; 4: 179–86

    Article  PubMed  CAS  Google Scholar 

  111. Giudici D, Ornati G, Briatico G, et al. 6-Methylenandrosta-l,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988; 30: 391–4

    Article  PubMed  CAS  Google Scholar 

  112. Di Salle E, Giudici D, Ornati G, et al. 4-Aminoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1990; 37: 369–74

    Article  PubMed  Google Scholar 

  113. Johannessen DC, Engan T, di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997; 3: 1101–8

    PubMed  CAS  Google Scholar 

  114. Paridaens P, Thomas J, Wildiers J, et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 1998; 9(8): 675–83

    Article  PubMed  CAS  Google Scholar 

  115. Dowsett M, Mehta A, King N, et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 1992; 28: 415–20

    Article  PubMed  CAS  Google Scholar 

  116. Goss PE, Powles TJ, Dowsett M, et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986; 46: 4823–6

    PubMed  CAS  Google Scholar 

  117. Demers LM. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994; 30: 95–102

    Article  PubMed  CAS  Google Scholar 

  118. Santen RJ, Santner S, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257–65

    Article  PubMed  CAS  Google Scholar 

  119. Reed MJ, Aherne GW, Ghilchik MW, et al. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int J Cancer 1991; 49: 562–5

    Article  PubMed  CAS  Google Scholar 

  120. de Jong PC, van de Ven J, Nortier HWR, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 1997; 57: 2109–11

    PubMed  Google Scholar 

  121. Lonning PE. Stepwise estrogen suppression manipulating the estrostat. J Steroid Biochem Molec Biol 2001; 79: 127–32

    Article  PubMed  CAS  Google Scholar 

  122. Lønning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992; 22: 327–58

    Article  PubMed  Google Scholar 

  123. Marfil F, Pineau V, Sioufi A, et al. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J Chromatogr 1996; 683: 251–8

    Article  CAS  Google Scholar 

  124. Breda M, Pianezzola E, Benedetti MS. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1993; 620: 225–31

    Article  PubMed  CAS  Google Scholar 

  125. AboulEnein HY, Ali I, Gubitz G, et al. HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and am-ylose-based chiral stationary phases under reversed phase mode. Chirality 2000; 12(10): 727–33

    Article  CAS  Google Scholar 

  126. Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997; 18(9): 779–89

    Article  PubMed  CAS  Google Scholar 

  127. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharm Drug Dispos 1997; 18: 489–97

    Article  PubMed  CAS  Google Scholar 

  128. Evans TRJ, Salle ED, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52: 5933–9

    PubMed  CAS  Google Scholar 

  129. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543–8

    Article  PubMed  CAS  Google Scholar 

  130. Lønning PE, Paridaens R, Thürlimann B, et al. Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol 1997; 61(3–6): 151–5

    Article  PubMed  Google Scholar 

  131. Murray M, Cantrill E, Farrell GC. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther 1993; 265: 477–81

    PubMed  CAS  Google Scholar 

  132. Lien EA, Anker G, Lønning PE, et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990; 50: 5851–7

    PubMed  CAS  Google Scholar 

  133. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br J Cancer 1999; 79(2): 311–5

    Article  PubMed  CAS  Google Scholar 

  134. Ingle JN, Suman VJ, Jordan VC, et al. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999; 6: 265–9

    Article  PubMed  CAS  Google Scholar 

  135. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338–43

    PubMed  CAS  Google Scholar 

  136. Baum M, Dowsett M, Coibion M, et al. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial. Brit J Cancer 2001; 85(3): 317–24

    Article  Google Scholar 

  137. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9(6): 639–45

    Article  PubMed  CAS  Google Scholar 

  138. Harvey HA, Lipton A, White DS, et al. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 1982; 42 Suppl.: 3451s–3s

    PubMed  CAS  Google Scholar 

  139. Lipton A, Harvey HA, Santen RJ, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982; 42 Suppl.: 3434s–6s

    PubMed  CAS  Google Scholar 

  140. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised crossover trial. Br Med J 1981; 283: 1432–4

    Article  CAS  Google Scholar 

  141. Lundgren S, Gundersen S, Klepp R, et al. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 1989; 14: 201–6

    Article  PubMed  CAS  Google Scholar 

  142. Canney PA, Priestman TJ, Griffiths T, et al. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 1988; 80: 1147–51

    Article  PubMed  CAS  Google Scholar 

  143. Lønning PE. Aromatase inhibition: past, present and future. In: Dowsett M, editor. Endocrine aspects of breast cancer. Carnforth: Parthenon Publishing Group, 1992: 53–75

    Google Scholar 

  144. Volk H, Deupree RH, Goldenberg IS, et al. A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 1974; 33: 9–13

    Article  PubMed  CAS  Google Scholar 

  145. Judd HL, Barone RM, Laufer LR, et al. In vivo effects of delta 1-testololactone on peripheral aromatization. Cancer Res 1982; 42Suppl. 8: 3345–8

    CAS  Google Scholar 

  146. Segaloff A. Testololactone: clinical trials. Cancer Res 1982; 42Suppl. 8: 3387–8

    Google Scholar 

  147. Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996; 9(4): 292–306

    Article  PubMed  CAS  Google Scholar 

  148. Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306–12

    PubMed  CAS  Google Scholar 

  149. Rose C, Freue M, Kjaer M, et al. An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients [abstract PP-8-4]. 7th EORTC Breast Cancer Working Conference; 1996 Sep, Bordeaux

  150. Thürlimann B, Castiglione M, HsuSchmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 1997; 33(7): 1017–24

    Article  PubMed  Google Scholar 

  151. Vorobiof DA, Kleeberg UR, PerezCarrion R, et al. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex (R)) with intramuscular formestane in postmenopausal women with advanced breast cancer. Ann Oncol 1999; 10(10): 1219–25

    Article  PubMed  CAS  Google Scholar 

  152. Murray R, Pitt P. Aromatase inhibition with 4-OHandro-stenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995; 35: 249–53

    Article  PubMed  CAS  Google Scholar 

  153. Geisler J, Johannessen DC, Anker G, et al. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur J Cancer 1996; 32A(5): 789–92

    Article  PubMed  CAS  Google Scholar 

  154. Pérez-Carrión R, Candel VA, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5: S19–24

    Article  PubMed  Google Scholar 

  155. Costa LAM, Kopreski MS, Demers LM, et al. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS16949A) in postmenopausal women with breast carcinoma. Cancer 1999; 85(1): 100–3

    Article  PubMed  CAS  Google Scholar 

  156. Miller AA, Lipton A, Henderson IC, et al. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer 1996; 78(4): 789–93

    Article  PubMed  CAS  Google Scholar 

  157. Raats JI, Falkson G, Falkson HC. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 1992; 10: 111–6

    PubMed  CAS  Google Scholar 

  158. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HC1 (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multi-institutional trials. Cancer 1996; 77(12): 2503–13

    Article  PubMed  CAS  Google Scholar 

  159. Bezwoda WR, Gudgeon A, Falkson G, et al. Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer. Oncology 1998; 55(5): 416–20

    Article  PubMed  CAS  Google Scholar 

  160. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996; 7(5): 465–9

    Article  PubMed  CAS  Google Scholar 

  161. Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer -prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996; 7(5): 471–9

    Article  PubMed  Google Scholar 

  162. Jonat W, Howell A, Blomqvist C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A(3): 404–12

    Article  PubMed  CAS  Google Scholar 

  163. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997; 79: 730–9

    Article  PubMed  CAS  Google Scholar 

  164. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83(6): 1142–52

    Article  PubMed  CAS  Google Scholar 

  165. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16(2): 453–61

    PubMed  CAS  Google Scholar 

  166. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19(14): 3357–66

    PubMed  CAS  Google Scholar 

  167. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18: 1399–411

    PubMed  CAS  Google Scholar 

  168. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18(22): 3748–57

    PubMed  CAS  Google Scholar 

  169. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18(22): 3758–67

    PubMed  CAS  Google Scholar 

  170. Milla-Santos A, Milla L, Rallo L, et al. Anastrozole vs tamoxifen in hormonodependent advanced breast cancer: a phase II randomized trial [abstract no.173]. Breast Cancer Res Treat 2000; 64: 54

    Google Scholar 

  171. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606

    PubMed  CAS  Google Scholar 

  172. Dirix L, Piccart MJ, Lohrish C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organization for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001; 20: 29a

    Google Scholar 

  173. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999; 17(11): 3418–25

    PubMed  CAS  Google Scholar 

  174. Jones S, Chang A, Lusch C, et al. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen and megace [abstract no. 437]. Breast Cancer Res Treat 1998; 50: 305

    Google Scholar 

  175. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997; 33(11): 1767–73

    Article  PubMed  Google Scholar 

  176. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18(11): 2234–44

    PubMed  Google Scholar 

  177. HarperWynne C, Coombes RC. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 1999; 35(5): 744–6

    Article  CAS  Google Scholar 

  178. Carlini P, Frassoldati A, Casali A, et al. Formestane (FOR) a steroidal aromatase inhibitor (SAI) after failure of nonsteroidal aromatase inhibitors (nSAI)(anastrozole: ANZ and letrozole: LTZ): is a clinical benefit (CB) still possible? [Abstract 144P]. Ann Oncol 2000; 11Suppl. 4: 35

    Google Scholar 

  179. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36(8): 976–82

    Article  PubMed  CAS  Google Scholar 

  180. Jones S, Belt R, Cooper B, et al. A phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) [abstract no. 436]. Breast Cancer Res Treat 1998; 50: 304

    Google Scholar 

  181. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16(8): 2672–85

    PubMed  CAS  Google Scholar 

  182. von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999–2005

    Google Scholar 

  183. Geisler S, Lønning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61(6): 2505–12

    PubMed  CAS  Google Scholar 

  184. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001; 66(3): 191–9

    Article  PubMed  CAS  Google Scholar 

  185. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12(11): 1527–32

    Article  PubMed  CAS  Google Scholar 

  186. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230–6

    PubMed  CAS  Google Scholar 

  187. Samojlik E, Santen RJ, Worgul TJ. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin Endocrinol 1984; 20: 43–51

    Article  CAS  Google Scholar 

  188. Lønning PE, Dowsett M, Jones A, et al. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res Treat 1992; 23: 57–62

    Article  PubMed  Google Scholar 

  189. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595–601

    PubMed  CAS  Google Scholar 

  190. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67(2): 111–6

    Article  PubMed  CAS  Google Scholar 

  191. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141(1): 396–405

    Article  PubMed  CAS  Google Scholar 

  192. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190–7

    Article  PubMed  CAS  Google Scholar 

  193. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997; 76(7): 401–5

    Article  PubMed  CAS  Google Scholar 

  194. Dorgan JF, Longcope C, Stanczyk FZ, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91(4): 380–1

    Article  PubMed  CAS  Google Scholar 

  195. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88(5): 291–6

    Article  PubMed  CAS  Google Scholar 

  196. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90(17): 1292–9

    Article  PubMed  CAS  Google Scholar 

  197. Baum M. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal (PM) women [abstract]. Breast Cancer Res Treat 2001; 69: 210

    Google Scholar 

  198. Compston JE. Prevention and management of osteoporosis. Current trends and future prospects. Drugs 1997; 53(5): 727–35

    Article  PubMed  CAS  Google Scholar 

  199. Compston JE. Selective oestrogen receptor modulators: potential therapeutic applications. Clin Endocrinol 1998; 48(4): 389–91

    Article  CAS  Google Scholar 

  200. Dallongeville J, Marecaux N, Isorez D, et al. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123–33

    Article  PubMed  CAS  Google Scholar 

  201. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204

    Article  PubMed  CAS  Google Scholar 

  202. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85(1): 214–8

    Article  PubMed  CAS  Google Scholar 

  203. Anker G, Lønning PE, Ueland PM, et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365–8

    Article  PubMed  CAS  Google Scholar 

  204. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327–32

    Article  PubMed  CAS  Google Scholar 

  205. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860–4

    PubMed  CAS  Google Scholar 

  206. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6

    Article  PubMed  CAS  Google Scholar 

  207. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994; 12: 992–7

    PubMed  CAS  Google Scholar 

  208. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7

    Article  PubMed  CAS  Google Scholar 

  209. deValkdeRoo GW, Stehouwer CDA, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women -a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19(12): 2993–3000

    Article  CAS  Google Scholar 

  210. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -results from a 3-year randomized clinical trial. JAMA 1999; 282(7): 637–45

    Article  PubMed  CAS  Google Scholar 

  211. Hozumi Y, Kawano M, Saito T, et al. Relation between apolipoprotein E phenotype and the changes in lipids during tamoxifen treatment. Endocr J 1998; 45(2): 255–9

    Article  PubMed  CAS  Google Scholar 

  212. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84

    PubMed  CAS  Google Scholar 

  213. Love RR, Anker G, Yang YH, et al. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Lett 1999; 145(1–2): 73–7

    Article  PubMed  CAS  Google Scholar 

  214. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280: 605–13

    Article  CAS  Google Scholar 

  215. Alexander KP, Newby LK, Hellkamp AS. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Amer Coll Cardiol 2001; 38(1): 1–7

    Article  CAS  Google Scholar 

  216. Wojtacki J, Kruszewski W, Sliwinska M, et al. Effect of nonsteroidal aromatase inhibitors (AI) on serum lipids profile in patients with breast cancer. Preliminary report. Eur J Cancer 2000; 36Suppl. 5: s71, 146

    Google Scholar 

  217. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37(12): 1510–3

    Article  PubMed  CAS  Google Scholar 

  218. Lohrisch C, Paridaens R, Dirix LY, et al. No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacias Upjohn. Proc Am Soc Clin Oncol 2001; 20: 43a

    Google Scholar 

Download references

Acknowledgements

The work performed by the author’s own group was all supported by the Norwegian Cancer Society.

Author information

Authors and Affiliations

  1. Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, N-5021, Norway

    Per E. Lønning

Authors
  1. Per E. Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per E. Lønning.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lønning, P.E. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy. Drugs Aging 19, 277–298 (2002). https://doi.org/10.2165/00002512-200219040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219040-00003

Keywords

Search

Navigation